Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
×
News
Share this article
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Share on print
Print

Dapagliflozin recommended for approval as therapy for heart failure in the EU

The sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin has been recommended for an extension of its marketing authorisation in the EU to include treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF), in adults with and without type 2 diabetes. If approved, it would become the first SGLT2 inhibitor to receive this licence in the EU.
The recommendation, from the Committee for Medicinal Products for Human Use (CHMP), was based on results of the Phase 3 DAPA-HF study, which showed that dapagliflozin, in addition to the standard of care, reduced the risk of the composite outcome of cardiovascular death or worsening of HF by 26% compared with placebo, an absolute risk reduction of 4.9%.
John McMurray, the lead study author of DAPA-HF, said: “I am delighted that we may soon have a new treatment that is effective, safe and simple to use for patients with heart failure with reduced ejection fraction. Dapagliflozin is a major and welcome breakthrough with the potential to improve not only the quality, but also importantly, the length of life for millions of people suffering from this terrible disease in Europe and throughout the world.”

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.